The ADDF offers funding to researchers in both nonprofit and for-profit organizations for drug discovery, clinical trials,  biomarker development. Visit our Research Priorities for specific information about our interests.

ADDF FUNDING PORTAL

LOG IN OR
CREATE ACCOUNT

We provide applicants with a streamlined review process—the average time from letter of intent (LOI) decision to award decision is approximately four months. For most RFPs, letters of intent are accepted and reviewed on a rolling basis during four cycles each year, corresponding to our four invited full proposal reviews.

Read our policies on application submissions and funding.

CORE REQUESTS FOR PROPOSALS


Program to Accelerate Clinical Trials (PACT) RFP

Seeks to support Phase 0 through Phase 2 clinical trials, experimental medicine studies in human subjects, and IND-enabling studies.

 
 

Biomarkers Development RFP

Seeks to support the development and validation of novel and existing biomarkers that will enhance the design and performance of clinical trials for Alzheimer's disease, related dementias, and cognitive aging.

 
 

Prevention Beyond the Pipeline RFP

Seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.

 
 

Drug Discovery RFP

Seeks to support programs that advance novel lead molecules to the clinical candidate selection stage, or build preclinical evidence in relevant animal models for repurposed/repositioned drugs.

 

 

OTHER ADDF FUNDING OPPORTUNITIES


ADDF/NIH Funding

Supports NIA and NINDS grant proposals in NIH format that were scored but not funded, which fall within our mission and research priorities.

 
 

Conference Funding

Supports scientific conferences that are relevant to our mission with grants up to $10,000. For more information, email grants@alzdiscovery.org with a brief summary of your conference

 


Stay Updated on Upcoming Deadlines and RFP Announcements

Sign up to receive news by email.

Print